Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07024693 · ClinicalTrials.gov registry record · Phase 2
DT-168 in Keratoplasty Patients With Fuchs Endothelial Corneal Dystrophy
A Phase 2 study of Fuchs Endothelial Corneal Dystrophy and Fuchs, sponsored by Design Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 28
- Enrollment target
- 2
- Study locations
NCT07024693 is a Phase 2 study of Fuchs Endothelial Corneal Dystrophy and Fuchs that is actively recruiting participants, run by Design Therapeutics. The registered enrollment target is 28 participants, below the 58-participant average among 3 other Fuchs Endothelial Corneal Dystrophy trials with a reported enrollment target (52% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT07024693, a Phase 2 study of Fuchs Endothelial Corneal Dystrophy and Fuchs, is actively recruiting participants, sponsored by Design Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 28 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to evaluate the pharmacodynamics, safety, and tolerability of DT-168 Ophthalmic Solution in pre-keratoplasty patients with Fuchs endothelial corneal dystrophy.
Conditions Studied
Interventions
- DRUG DT-168
Study Locations (2)
Indiana
- DTX-168-201 Study Site - Indianapolis
Michigan
- DTX-168-201 Study Site - Grand Rapids
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2025-07-30 |
| Est. Completion | 2026-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07024693
The ClinicalTrials.gov registry entry for NCT07024693 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 58-participant average among 3 other Fuchs Endothelial Corneal Dystrophy trials with a reported enrollment target (52% lower). The listed sponsor is Design Therapeutics, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Fuchs Endothelial Corneal Dystrophy appearing as the primary indexed condition, and to 1 intervention - of which DT-168 is the first listed.
NCT07024693 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Indiana, Michigan.
Frequently Asked Questions
What is clinical trial NCT07024693 about?
NCT07024693 is a clinical study titled "DT-168 in Keratoplasty Patients With Fuchs Endothelial Corneal Dystrophy". The purpose of this study is to evaluate the pharmacodynamics, safety, and tolerability of DT-168 Ophthalmic Solution in pre-keratoplasty patients with Fuchs endothelial corneal dystrophy.
What is the current status of trial NCT07024693?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2025-07-30. Estimated completion is 2026-12.
What conditions does trial NCT07024693 study?
This clinical trial studies the following conditions: Fuchs Endothelial Corneal Dystrophy, Fuchs.
What interventions are being tested in trial NCT07024693?
The interventions under investigation include: DT-168 (DRUG).
Who is sponsoring clinical trial NCT07024693?
This trial is sponsored by Design Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07024693 being conducted?
This trial has 2 study locations across Indiana, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Fuchs Endothelial Corneal Dystrophy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Targeting Reactive Oxygen Species Production as a Novel Therapeutic in Fuch's Endothelial Corneal Dystrophy
RECRUITING · Phase 2
-
A Phase 1/ Phase 2 Study of TTHX1114(NM141)
COMPLETED · Phase 1
-
A Study to Evaluate the Safety and Efficacy of K-321 Eye Drops After Descemetorhexis in Participants With Fuchs Endothelial Corneal Dystrophy (FECD)
COMPLETED · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.